tiprankstipranks
Trending News
More News >
Becton Dickinson And Company (BDX)
NYSE:BDX
US Market

Becton Dickinson (BDX) Earnings Dates, Call Summary & Reports

Compare
2,091 Followers

Earnings Data

Report Date
Apr 30, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
2.25
Last Year’s EPS
2.63
Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:Feb 09, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call balances strong strategic and operational progress — closing the Waters RMT, $4 billion cash distribution, targeted share repurchases and debt paydown, solid commercial momentum across key growth platforms (double-digit growth in multiple areas), improved free cash flow conversion, and meaningful productivity gains — against notable near-term financial headwinds including tariff-driven margin pressure, China price dynamics, vaccine demand softness, and Alaris remediation-related revenue impacts. Management provided prudent guidance (low single-digit revenue growth and EPS range) while emphasizing investments in high-growth, higher-margin areas, tuck-in M&A focus, and continued margin improvement actions.
Company Guidance
Management guided New Becton, Dickinson and Company for FY‑2026 to low single‑digit revenue growth (Q2 ~2%, and an FX tailwind of ~120 bps), with adjusted EPS of $12.35–$12.65 (midpoint ≈ $12.50, ~6% growth at midpoint, including a ~370‑bp tariff headwind) and adjusted operating margin of about 25% (inclusive of tariffs); they expect interest & other, net of $600–$620M, an adjusted tax rate of 16–17%, and ~282M weighted average shares. The Waters separation yields a $4B cash distribution (to be deployed ~$2B to an ASR and ~$2B to debt paydown) with a net estimated EPS impact of ~ $2.4, leaving operational guidance unchanged. Q2 adjusted EPS was guided to $2.72–$2.82; Q1 free cash flow was $548M (66% conversion vs 59% prior), the company returned ~ $550M to shareholders in the quarter (including $250M buybacks), and ended the quarter at 2.9x net leverage (versus a 2.5x long‑term target).
Revenue and New Company Growth
Total Q1 revenue of $5.3 billion, up 0.4% year-over-year; New Becton, Dickinson and Company (post-Life Sciences transaction) grew 2.5% YoY, with mid-single-digit growth across ~90% of the NewCo portfolio.
Strong Performance in Key Growth Platforms
Double-digit growth in biologic drug delivery (GLP-1), PureWick, advanced tissue regeneration, and pharmacy automation; high single-digit growth in advanced patient monitoring (APM). Over 80 GLP-1 novel and biosimilar molecules contracted.
Adjusted EPS and Margin Results Beat Expectations
Adjusted EPS of $2.91 (despite a 15.2% YoY decline) and adjusted gross margin of 53.4% were both ahead of the company’s expectations, driven by revenue strength and operational execution.
Significant Corporate Transaction and Cash Deployment
Closed combination of Life Sciences business with Waters via Reverse Morris Trust; received $4.0 billion cash distribution — $2.0 billion to be deployed to share repurchases (ASR) and $2.0 billion to pay down debt.
Shareholder Returns and Balance Sheet Actions
Returned approximately $550 million to shareholders in Q1 (dividends + $250 million buybacks); announced immediate $2.0 billion ASR and $2.0 billion debt repayment from the Waters distribution; net leverage 2.9x with clear plan to move toward 2.5x target.
Operational Productivity and Cost Actions
Becton, Dickinson and Company Excellence drove an 8% productivity improvement in the quarter and $150 million (75%) of the targeted $200 million cost-out program executed, supporting margins and cash flow.
Free Cash Flow and Conversion Improvement
Generated $548 million of free cash flow in the quarter; free cash flow conversion improved to 66% from 59% year-over-year due to working capital discipline and capital efficiency.
Commercial Momentum and Product Launches
Pyxis Pro launch strong with 85% of initial orders from competitive conversions; Alaris saw the strongest quarter of competitive wins since relaunch (category share up ~100 bps in the quarter); launches and submissions include Avitene Flowable (U.S.), SurgiFor (Europe), SurgiFore Pulse (FDA submission), and HemoSphere Stream (targeted release).

Becton Dickinson (BDX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

BDX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 30, 2026
2026 (Q2)
2.25 / -
2.633
Feb 09, 2026
2026 (Q1)
2.21 / 2.29
2.695-15.14% (-0.41)
Nov 06, 2025
2025 (Q4)
3.08 / 3.11
2.9943.94% (+0.12)
Aug 07, 2025
2025 (Q3)
2.67 / 2.89
2.755.16% (+0.14)
May 01, 2025
2025 (Q2)
2.58 / 2.63
2.4915.70% (+0.14)
Feb 05, 2025
2025 (Q1)
2.34 / 2.69
2.10627.97% (+0.59)
Nov 07, 2024
2024 (Q4)
2.96 / 2.99
2.68811.38% (+0.31)
Aug 01, 2024
2024 (Q3)
2.60 / 2.75
2.32618.23% (+0.42)
May 02, 2024
2024 (Q2)
2.33 / 2.49
2.24810.81% (+0.24)
Feb 01, 2024
2024 (Q1)
1.89 / 2.11
2.342-10.08% (-0.24)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

BDX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 09, 2026
$165.04$162.98-1.25%
Nov 06, 2025
$137.87$138.65+0.57%
Aug 07, 2025
$134.03$145.90+8.86%
May 01, 2025
$160.02$131.01-18.13%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Becton Dickinson And Company (BDX) report earnings?
Becton Dickinson And Company (BDX) is schdueled to report earning on Apr 30, 2026, Before Open (Confirmed).
    What is Becton Dickinson And Company (BDX) earnings time?
    Becton Dickinson And Company (BDX) earnings time is at Apr 30, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is BDX EPS forecast?
          BDX EPS forecast for the fiscal quarter 2026 (Q2) is 2.25.

            Becton Dickinson (BDX) Earnings News

            Becton Dickinson to Split from Bioscience and Diagnostic Solutions Arms
            Premium
            Market News
            Becton Dickinson to Split from Bioscience and Diagnostic Solutions Arms
            1y ago